10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis

Virchow's Triad & Molecular Pathophysiology in the Puerperium

Venous thromboembolism (VTE)—encompassing Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Septic Pelvic Thrombophlebitis (SPT)—remains one of the top direct causes of maternal mortality in the United States and developed nations. The vulnerability of the postpartum patient to thromboembolic occlusion is driven by the convergence of all three elements of Virchow's Triad:

+---------------------------------------------------------------------------------------------------+
|                             VIRCHOW'S TRIAD IN PREGNANCY & POSTPARTUM                             |
+---------------------------------------------------------------------------------------------------+
                                                  │
                    ┌─────────────────────────────┼─────────────────────────────┐
                    ▼                             ▼                             ▼
      [ 1. HYPERCOAGULABILITY ]         [ 2. VENOUS STASIS ]          [ 3. ENDOTHELIAL INJURY ]
      • Marked rise in Factors I,       • Gravid uterus compresses    • Shearing delivery trauma
        II, VII, VIII, X, & vWF           IVC & Iliac veins             to pelvic & uterine veins
      • Downregulation of Protein S     • Progesterone-mediated       • Cesarean uterine incision
      • Acquired Protein C resistance     venodilation & pooling        and operative manipulation
      • PAI-1 and PAI-2 surge           • Bed rest / immobility       • Endometrial decidual
        (blunted fibrinolysis)            (cesarean, magnesium)         detachment & raw vessels
                    │                             │                             │
                    └─────────────────────────────┼─────────────────────────────┘
                                                  │
                                                  ▼
                     [ SURGE IN POSTPARTUM THROMBOSIS FORMATION ]
                     • VTE risk is 20-80x higher than non-pregnant baseline
                     • Peak vulnerability occurs during first 3 to 6 weeks postpartum

Left-Sided Predilection & The May-Thurner Phenomenon

In non-pregnant populations, DVTs occur equally across right and left lower extremities. In pregnant and postpartum individuals, however, over 80% to 90% of all DVTs develop in the LEFT lower extremity, with a disproportionately high incidence of iliofemoral (proximal) and pelvic venous thrombosis:

1. May-Thurner Anatomy: The left common iliac vein crosses beneath the pulsating right common iliac artery, where it is mechanically compressed against the prominent 5th lumbar vertebra.
2. Uterine Dextrorotation: As the gravid uterus enlarges, it naturally undergoes dextrorotation (tilting to the right), exerting direct mechanical compression on the left common iliac vein and dramatically increasing venous pressure and stasis throughout the left leg and pelvic venous plexus.
3. Clinical Implication: Iliofemoral DVTs carry a substantially higher risk of massive pulmonary embolism and post-thrombotic syndrome compared to distal calf vein thrombi.

Clinical Manifestations & Diagnostic Algorithms for DVT and PE

+---------------------------------------------------------------------------------------------------+
|                         CLINICAL PRESENTATION OF DVT AND PULMONARY EMBOLISM                       |
+---------------------------------------------------------------------------------------------------+

    ┌───────────────────────────────────┬───────────────────────────────────┐
    │ DEEP VEIN THROMBOSIS (DVT)        │ PULMONARY EMBOLISM (PE)           │
    ├───────────────────────────────────┼───────────────────────────────────┤
    │ • Unilateral lower extremity pain │ • Sudden-onset acute dyspnea      │
    │ • Swelling, edema, tightness      │ • Pleuritic chest pain (sharp)    │
    │ • Calf/thigh circumference        │ • Tachypnea (RR >20-24 bpm)       │
    │   asymmetry (>2 cm difference)    │ • Tachycardia (HR >100-110 bpm)   │
    │ • Localized warmth, erythema      │ • Hemoptysis, dry cough, syncope  │
    │ • Tenderness along deep venous cord│ • Hypoxemia (SpO2 <95% room air)  │
    │ • (Homan's sign is unreliable     │ • Sudden apprehension, anxiety    │
    │    and NOT recommended)           │ • Right heart strain on EKG (S1Q3T3)│
    └───────────────────────────────────┴───────────────────────────────────┘

Diagnostic Pathway for Suspected DVT

• D-Dimer Limitations: Serum D-dimer levels naturally rise progressively throughout pregnancy and remain elevated for 4 to 6 weeks postpartum due to physiologic fibrin turnover. A positive D-dimer has almost zero specificity in postpartum patients. (A negative high-sensitivity D-dimer can rule out DVT in low-risk antepartum patients, but has limited utility in the immediate inpatient puerperium).
• Primary Imaging Modality: Compression Duplex Ultrasonography (CUS) with Color Doppler of the entire proximal and distal venous tree of the symptomatic extremity.
• Loss of Compressibility: The definitive diagnostic criterion for DVT is the inability to completely collapse/compress the vein lumen under direct transducer pressure.
• Pelvic / Iliofemoral Suspicion: If the patient has severe unilateral groin/thigh/back pain and swelling, but lower-extremity CUS is negative, the clot may be located higher in the internal/external iliac or ovarian veins. Perform dedicated pelvic Doppler ultrasound or Magnetic Resonance Venography (MRV).

+---------------------------------------------------------------------------------------------------+
|                         DIAGNOSTIC ALGORITHM FOR SUSPECTED MATERNAL PE                            |
+---------------------------------------------------------------------------------------------------+
                                                  │
                               [ Patient Presents with Acute Dyspnea / Pleuritic Pain ]
                                                  │
                                                  ▼
                               [ Initial Assessment & Bilateral Leg CUS ]
                        ┌─────────────────────────┴─────────────────────────┐
                        ▼                                                   ▼
              [ CUS IS POSITIVE ]                                  [ CUS IS NEGATIVE ]
              • DVT confirmed                                      • Proceed immediately to definitive
              • Initiate therapeutic anticoagulation                 chest imaging without delay
              • Further chest imaging NOT required                                  │
                (treatment is identical)                                            ▼
                                                                   [ CHEST X-RAY (CXR) ]
                                                    ┌───────────────────────┴───────────────────────┐
                                                    ▼                                               ▼
                                          [ NORMAL CHEST X-RAY ]                  [ ABNORMAL CHEST X-RAY ]
                                          • Ventilation-Perfusion                 • CT Pulmonary Angiography
                                            (V/Q) Scan Preferred                    (CTPA) Preferred
                                          • (Lower radiation to                   • (Evaluates for pneumonia,
                                             maternal breast tissue)                 effusion, atelectasis, PE)

CLINICAL RADIATION SAFETY NOTE: Fear of fetal or maternal radiation must NEVER delay definitive diagnostic imaging for a suspected life-threatening pulmonary embolism. The fetal radiation dose from a CTPA or V/Q scan is negligible (<0.1 mGy, far below the 50 mGy teratogenic threshold), and contrast agents used in CTPA do not harm lactation.

Anticoagulation Pharmacology & Management in Pregnancy and Lactation

+---------------------------------------------------------------------------------------------------+
|                         PHARMACOTHERAPY MATRIX FOR MATERNAL ANTICOAGULATION                       |
+---------------------------------------------------------------------------------------------------+

  DRUG CLASS           AGENTS & DOSING                  SAFETY IN LACTATION     KEY CLINICAL RULES
  -------------------  -------------------------------  ----------------------  --------------------------------------------------
  Low-Molecular-Weight  ENOXAPARIN (Lovenox)             SAFE IN BREASTFEEDING   • Drug of choice in pregnancy & postpartum.
  Heparin (LMWH)       • Prophylactic: 40 mg SC daily   (Minimal excretion,     • Does not cross the placenta (large molecule).
                       • Intermediate: 40 mg SC q12h    negligible oral         • Monitored via Anti-Xa levels (target 0.6-1.0
                       • Therapeutic: 1 mg/kg SC q12h   bioavailability)          IU/mL for therapeutic dosing 4h post-injection).
                                                                                • Hold 12h (prophylactic) or 24h (therapeutic)
                                                                                  prior to neuraxial anesthesia.
  -------------------  -------------------------------  ----------------------  --------------------------------------------------
  Unfractionated       HEPARIN SODIUM (UFH)             SAFE IN BREASTFEEDING   • Preferred near term/delivery and in severe renal
  Heparin (UFH)        • Prophylactic: 5,000-7,500 U SC (Large molecule, does     failure (GFR <30 mL/min).
                       • Therapeutic: 80 U/kg bolus,      not cross into milk)  • Short half-life (1-2 hours).
                         then 18 U/kg/hr IV titration                           • Fully reversible with PROTAMINE SULFATE.
                         (Target aPTT 1.5-2.5x control)                         • Hold 4-6h (IV) or 12h (SC) prior to neuraxial.
  -------------------  -------------------------------  ----------------------  --------------------------------------------------
  Vitamin K Antagonist WARFARIN (Coumadin)              SAFE IN BREASTFEEDING   • STRICTLY CONTRAINDICATED IN PREGNANCY
                       • Postpartum dosing: Titrate     (Highly protein-bound,    (Warfarin embryopathy, nasal hypoplasia, CNS
                         INR to target 2.0-3.0            does not enter milk)    defects, fetal hemorrhage).
                                                                                • Safe to initiate in POSTPARTUM LACTATING patients.
  -------------------  -------------------------------  ----------------------  --------------------------------------------------
  Direct Oral          RIVAROXABAN (Xarelto)            CONTRAINDICATED IN      • STRICTLY CONTRAINDICATED IN PREGNANCY AND
  Anticoagulants       APIXABAN (Eliquis)               LACTATION                 LACTATION due to excretion into breast milk
  (DOACs)              DABIGATRAN (Pradaxa)                                       and lack of safety data in neonates.
+---------------------------------------------------------------------------------------------------+

Neuraxial Anesthesia & Anticoagulation Timing Rules (ASRA Guidelines)

To prevent catastrophic spinal/epidural hematoma (which causes irreversible lower extremity paralysis and spinal cord compression), strict adherence to American Society of Regional Anesthesia and Pain Medicine (ASRA) timing guidelines is mandatory:

1. Prophylactic LMWH (e.g., Enoxaparin 40 mg SC daily): Neuraxial placement or catheter removal must be delayed for a minimum of 12 hours following the last dose.
2. Therapeutic LMWH (e.g., Enoxaparin 1 mg/kg SC q12h): Neuraxial placement or catheter removal must be delayed for a minimum of 24 hours following the last dose.
3. Intravenous Unfractionated Heparin (Therapeutic Infusion): Stop infusion 4 to 6 hours prior to neuraxial placement; verify normal coagulation status (aPTT and platelet count).
4. Post-Procedure Anticoagulation Resumption:
   • Prophylactic LMWH may be resumed 4 to 6 hours after epidural catheter removal or uncomplicated delivery.
   • Therapeutic LMWH must be delayed for at least 24 hours following epidural catheter removal or major surgical delivery.

Septic Pelvic Thrombophlebitis (SPT) & Ovarian Vein Thrombosis (OVT)

Septic Pelvic Thrombophlebitis (SPT) is an uncommon, potentially lethal puerperal complication occurring in approximately 1 in 2,000 to 1 in 3,000 deliveries (substantially more frequent after cesarean birth following chorioamnionitis). SPT occurs when pelvic microbial infection (endometritis) extends into the pelvic and ovarian venous networks, damaging the vascular endothelium and triggering infected thrombus formation within the lumen of the pelvic veins.

+---------------------------------------------------------------------------------------------------+
|                         TWO CLINICAL VARIANTS OF SEPTIC PELVIC THROMBOPHLEBITIS                   |
+---------------------------------------------------------------------------------------------------+

    ┌───────────────────────────────────┬───────────────────────────────────┐
    │ 1. OVARIAN VEIN THROMBOSIS (OVT)  │ 2. DEEP SEPTIC PELVIC THROMBOSIS  │
    ├───────────────────────────────────┼───────────────────────────────────┤
    │ • Involves main ovarian vein      │ • Involves small, deep pelvic     │
    │ • 90% occur in the RIGHT ovarian  │   venous plexus (hypogastric,     │
    │   vein (due to right dextrorotation│   uterine, vaginal veins)         │
    │   and longer right ovarian vein)  │ • Lack localized abdominal pain   │
    │ • Symptoms: Acute, localized lower│ • Symptoms: Persistent, swinging  │
    │   quadrant flank/abdominal pain,  │   "picket-fence" spiking fevers   │
    │   palpable ropelike mass, fever,  │   without localizing pain/signs   │
    │   chills, tachycardia             │ • Known as "Enigmatic Fever"      │
    │ • Visible on contrast CT / MRI    │ • Often a diagnosis of exclusion  │
    └───────────────────────────────────┴───────────────────────────────────┘

Clinical Presentation & Diagnostic Confirmation

• The Hallmark Clinical Picture: The classic clinical presentation is a postpartum patient treated for endometritis who exhibits persistent, high-spiking, swinging "picket-fence" fevers (39.0°C–40.0°C / 102.2°F–104.0°F) and tachycardia despite 48 to 72 hours of appropriate broad-spectrum intravenous antimicrobial therapy (e.g., clindamycin + gentamicin + ampicillin), with otherwise negative physical findings and blood/urine cultures.
• Definitive Diagnostic Imaging: Contrast-enhanced Computed Tomography (CT) of the abdomen and pelvis or Magnetic Resonance Imaging (MRI) is the diagnostic modality of choice, demonstrating a thrombosed, enlarged, thick-walled ovarian vein with surrounding inflammatory stranding.

Treatment Protocol & The Therapeutic Trial

1. Therapeutic Anticoagulation: Initiate therapeutic IV Unfractionated Heparin (target aPTT 1.5–2.5x control) or therapeutic LMWH (Enoxaparin 1 mg/kg SC q12h).
2. Broad-Spectrum Intravenous Antibiotics: Continue or escalate to broad-spectrum coverage (e.g., Ampicillin-Sulbactam, Piperacillin-Tazobactam, or Clindamycin + Gentamicin + Ampicillin).
3. The "Heparin Defervescence Test": Historically, rapid defervescence (resolution of fever within 48 to 72 hours of initiating therapeutic heparin) was considered diagnostic confirmation of SPT.
4. Duration of Therapy: Continue IV antibiotics until the patient has been afebrile and asymptomatic for 48 hours; therapeutic anticoagulation is maintained for 2 to 6 weeks (or up to 3 months if extensive proximal clot propagation or pulmonary emboli are documented).